LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

Search

Simulations Plus Inc

Închisă

SectorSănătate

17.51 2.16

Rezumat

Modificarea prețului

24h

Curent

Minim

16.94

Maxim

17.68

Indicatori cheie

By Trading Economics

Venit

-70M

-67M

Vânzări

-2.1M

20M

P/E

Medie Sector

48.528

77.256

Randament dividend

0.48

Marjă de profit

-330.585

Angajați

243

EBITDA

327K

5.3M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-6.87% downside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.48%

2.33%

Următoarele câștiguri

1 dec. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-5.6M

346M

Deschiderea anterioară

15.35

Închiderea anterioară

17.51

Sentimentul știrilor

By Acuity

50%

50%

180 / 374 Clasament în Healthcare

Simulations Plus Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 nov. 2025, 23:59 UTC

Câștiguri

Singtel's 1st Half Net Profit Surges

11 nov. 2025, 22:23 UTC

Achiziții, Fuziuni, Preluări

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov. 2025, 22:21 UTC

Câștiguri

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov. 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov. 2025, 23:44 UTC

Câștiguri

Singtel's 1H Net Profit Surges

11 nov. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov. 2025, 23:18 UTC

Câștiguri

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov. 2025, 23:15 UTC

Câștiguri

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov. 2025, 23:14 UTC

Câștiguri

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov. 2025, 23:12 UTC

Câștiguri

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov. 2025, 23:11 UTC

Câștiguri

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov. 2025, 23:10 UTC

Câștiguri

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov. 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Health Care Roundup: Market Talk

11 nov. 2025, 21:46 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov. 2025, 21:41 UTC

Câștiguri

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov. 2025, 21:40 UTC

Câștiguri

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov. 2025, 21:39 UTC

Câștiguri

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov. 2025, 21:39 UTC

Câștiguri

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov. 2025, 21:39 UTC

Câștiguri

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov. 2025, 21:38 UTC

Câștiguri

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov. 2025, 21:38 UTC

Câștiguri

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov. 2025, 21:37 UTC

Câștiguri

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov. 2025, 21:36 UTC

Câștiguri

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov. 2025, 21:35 UTC

Câștiguri

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov. 2025, 21:35 UTC

Câștiguri

Alcon 3Q Adj EPS 79c >ALC

11 nov. 2025, 21:35 UTC

Câștiguri

Alcon 3Q Rev $2.61B >ALC.EB

11 nov. 2025, 21:35 UTC

Câștiguri

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov. 2025, 21:35 UTC

Câștiguri

Alcon 3Q EPS 48c >ALC.EB

Comparație

Modificare preț

Simulations Plus Inc Așteptări

Obiectiv de preț

By TipRanks

-6.87% jos

Prognoză pe 12 luni

Medie 16 USD  -6.87%

Maxim 16 USD

Minim 16 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSimulations Plus Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

180 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat